Objective: To study clinical efficacy of Herba Hedyotidis Diffusae as major prescription combining the radiotherapy in treating esophageal cancer for the guidance of the better treatment. Method: Eighty patients with esophageal in our hospital during the period from Jan 2010 to Jan 2013 were randomized into the control group (radiotherapy) and the observation group (Herba Hedyotidis Diffusae combined with radiotherapy). The clinical efficacy

life quality and the occurrence of adverse reaction of patients in two groups after treatment

and the tumor necrosis factor-β(TNF-β)

high sensitive C creactive protein (hs-CRP)

serum tumor markers such as CA125 and CEA in the two groups were observed. Result: Compared with the control group

the total effective rate was significantly increased (60.0% vs 42.5%) and the life quality was obviously impoved (80.0% vs 62.5%) in the observation group after treatment

P<0.05.The comparison of adverse reactions during the treatment period between the two groups was not statistical difference. Compared with the control group

the levels of TNF-β and hs-CRP were significantly reduced (P<0.05)

the comparison of CA125 and CEA levles were not statistical difference. Conclusion: The prescription mainly consisting of Herba Hedyotidis Diffusae as major prescription combining with the chemotherapy in treating esophageal cancer delivers significant effect

and it can effectively improve the life quality of patients

extend two-year survival rate of patient

and less adverse reactions are found

being worthy of clinical promotion.